Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feederfiercebiotech.com
FierceBiotech
Get the latest updates from FierceBiotech directly as they happen.
Follow now 283 followers
Latest posts
Last updated about 20 hours ago
Galectin’s MASH treatment reduces varices, but fails to hit statistical significance in phase 3 trial
about 20 hours ago
Galectin Therapeutics’ stock has halved since the company revealed its investigational drug...
Clinical research company Javara lays off employees as part of restructuring
about 22 hours ago
Clinical research firm Javara has laid off staff as part of a...
Applied Therapeutics CEO steps down in wake of FDA rejection, warning letter and investor lawsuit
about 22 hours ago
A turbulent month at Applied Therapeutics is being capped off with the...
Sanofi scoops up China rights to Cytokinetics’ heart disease med ahead of approval decision
about 24 hours ago
As Cytokinetics’ aficamten awaits approval decisions from regulators in the U.S. and...
Apollomics, after giving up on GlycoMimetics' leukemia therapy, posts drug's latest phase 3 fail
1 day ago
The failure of Apollomics’ myeloid leukemia drug in a phase 3 trial...
ElectroCore to buy NeuroMetrix and its Quell fibromyalgia wearable stimulator
1 day ago
The deal, valued at about $9 million in cash to start, will...
Novo Nordisk stock crashes after CagriSema misses phase 3 weight-loss goal
1 day ago
A phase 3 trial of Novo Nordisk’s next-generation obesity prospect CagriSema has...
Chutes & Ladders—FDA's principal deputy to depart agency
1 day ago
After less than a year on the job, the FDA’s principal deputy...
Pyxis Oncology shelves antibody to focus on sole clinical asset, an ADC licensed from Pfizer
1 day ago
Pyxis Oncology is shelving a clinical-stage monoclonal antibody to focus on its...
Oncology biotech Epitopea licenses Genevant nucleic acid delivery tech for up to $123M
1 day ago
To develop RNA medicines targeting a proprietary bundle of tumor antigens, Epitopea...
Idorsia’s sale of Tryvio falls behind schedule, but layoffs remain on track
1 day ago
Idorsia’s plans to sell its hypertension drug Tryvio have faced a speedbump...
Aadi pulls commercial-to-preclinical pivot, buying ADCs and selling approved drug to reboot business
1 day ago
Aadi Bioscience has rebooted its operations, transforming from a commercial business into...